Aging leads to increased cellular senescence and is associated with decreased potency of tissue-specific stem/progenitor cells. Here we have done an extensive analysis of cardiac progenitor cells (CPCs) isolated from human subjects with cardiovascular disease (n=119), aged 32-86 years. In aged subjects (>74 years old) over half of CPCs are senescent (p16 INK4A , SA-β-gal, DNA damage γH2AX, telomere length, Senescence-Associated Secretory Phenotype (SASP)), unable to replicate, differentiate, regenerate or restore cardiac function following transplantation into the infarcted heart. SASP factors secreted by senescent CPCs renders otherwise healthy CPCs to senescence. Elimination of senescent CPCs using senolytics abrogates the SASP and its debilitative effect in vitro. Global elimination of senescent cells in aged mice (INK-ATTAC or wildtype mice treated with D+Q senolytics) in vivo activates resident CPCs (0.23±0.06% vs. 0.01±0.01% vehicle; p<0.05) and increased the number of small, proliferating Ki67-, EdU-positive cardiomyocytes (0.25±0.07% vs. 0.03±0.03% vehicle; p<0.05). Therapeutic approaches that eliminate senescent cells may alleviate cardiac deterioration with aging and rejuvenate the regenerative capacity of the heart.
Introduction
Ageing is the greatest risk factor for many life-threatening disorders, including cardiovascular diseases, neurodegenerative diseases, cancer, and metabolic syndromes [1] . Although longterm exposure to known cardiovascular risk factors strongly drives the development of cardiovascular pathologies, intrinsic cardiac aging is considered to highly influence the pathogenesis of heart disease [2] . However, the fields of the biology of aging and cardiovascular disease have been studied separately, and only recently their intersection has begun to receive the appropriate attention.
Aging leads to increased cellular senescence in a number of tissues and work suggests senescent cell burden can be dramatically increased in various tissues and organs with chronological ageing or in models of progeria [3] [4] [5] . Cellular senescence is associated with increased expression of the senescence biomarker, p16 Ink4a (also known as Cdkn2a), impaired proliferation and resistance to apoptosis [6] [7] [8] [9] [10] . Senescent cells disrupt tissue structure and function because of the components they secrete, which act on adjacent as well as distant cells, causing fibrosis, inflammation, and a possible carcinogenic response [10] . Indeed, senescent cells possess a senescence-associated secretory phenotype (SASP), consisting of pro-inflammatory cytokines, chemokines and ECM-degrading proteins, which have deleterious paracrine and systemic effects [10] [11] [12] [13] . Remarkably, even a relatively low abundance of senescent cells (10-15% in aged primates) is sufficient to cause tissue dysfunction [14] .
To test whether senescent cells are causally implicated in age-related dysfunction and whether their removal is beneficial, J. L. Kirkland, T. Tchkonia, D. Baker (Mayo), J. van Deursen (Mayo) and colleagues made use of the biomarker for senescence, p16 INK4a , and an inducible "suicide" gene designed by P. Scherer et al. [15] to develop a novel transgene, INK-ATTAC, to permit inducible elimination of p16 INK4a -positive senescent cells upon administration of a drug (AP20187) [9] . In these mice, eliminating a relatively small proportion (~30%) of senescent cells extends health span and prevents the development of multiple age-related morbidities in both progeroid and normal, chronologically aged mice [9, [16] [17] [18] [19] [20] . Moreover, late life clearance attenuated the progression of already established agerelated disorders [20] . In an effort to be applicable to humans, Kirkland and collaborators have identified a new class of drugs named senolytics. Through exploiting senescent cells' dependence on specific pro-survival pathways, senolytics specifically kill senescent cells without affecting proliferating or quiescent, differentiated cells [21] [22] [23] . Recent studies have documented the use of senolytic drugs for the selective clearance of senescent cells from 'aged' tissues [16, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . Indeed, a combination of senolytics drugs (D, dasatinib, a FDAapproved tyrosine kinase inhibitor; and Q, quercetin, a flavonoid present in many fruits and vegetables), administered to 20-month-old male C57BL/6 mice once monthly for 4 months, led to significantly lower senescent (p16 Ink4a -and SA-β-gal-expressing) cells in aorta, bone, adipose tissue, skeletal muscle, and kidney [11, [16] [17] [18] [19] [20] 24] . Whether eliminated genetically or through senolysis, it's been shown that removal of p16 Ink4a senescent cells can delay the acquisition of age-related pathologies in adipose tissue, skeletal muscle, heart, blood vessels, lung, liver, bone, and eye [9, 11, 12, [16] [17] [18] [19] [20] [24] [25] [26] [27] [28] . Recently, the Kirkland lab has demonstrated that transplanting relatively small numbers of senescent preadipocyte cells into young (6 month old) mice causes persistent physical dysfunction, measured through maximal speed, hanging endurance and grip strength, 1 month after transplantation. Transplanting even fewer senescent cells into older (17 month old) recipients had the same effect and reduced survival, indicating the potency of senescent cells in shortening health-and lifespan.
Intermittent oral administration of the senolytics, D and Q to senescent cell-transplanted young mice and naturally aged mice alleviated physical dysfunction and increased posttreatment survival by 36% while reducing mortality hazard to 65% [20] . Altogether these data indicate that cellular senescence is causally implicated in generating age-related phenotypes and that systemic removal of senescent cells can prevent or delay tissue dysfunction, physical dysfunction and extend health-and lifespan.
Mammalian aging is associated with gradual loss of the capacity of the tissue-specific stem/progenitor cells to maintain tissue homeostasis or to repair and regenerate tissues after injury or stress [29] . Indeed, in most tissues there is an overlap between aging and stem cell impairment [30] [31] [32] [33] . Function of tissue-specific stem cells declines with age due to several factors including telomere shortening, increased senescence and elevated expression of p16 Ink4a and other cyclin-dependent kinase inhibitors (CDKIs) [34] , DNA damage and external influences affecting stem cell niche homeostasis [30, [35] [36] [37] [38] . Like other organs, the adult mammalian heart has the capacity, albeit low, to self-renew cardiomyocytes over the human lifespan [39] , and genetic fate mapping models show that one source of new cardiomyocytes are a population of resident stem cells [40, 41] . Multiple labs [40, [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] have shown the mammalian heart, including human, to harbour a rare population of selfrenewing, clonogenic, multipotent cardiac stem/progenitor cells (CSCs or CPCs; abbreviated hereafter as CPCs) with regenerative potential in vivo [40, 43-46, 48, 50, 56-58] . An undisputed mechanism of action of CPC transplantation is their secretome reparative potential, which through acting in a paracrine manner improves cardiomyocyte survival [59] [60] [61] , limits fibrosis [60] [61] [62] , induces angiogenesis [59, 61, 63] , and new cardiomyocyte formation [62] [63] [64] and restores cardiac function [57, 59, 60, [64] [65] [66] . Recently, considerable confusion has emanated over the significant cardiomyogenic potential of CPCs purported using Kitcre Knockin or dual recombinases-mediated cell tracking mice models [67] [68] [69] .
However, these models do not tag or specifically lineage trace the CPCs, neither have the investigators isolated, characterised or transplanted CPCs to test their stem cell and regenerative properties. Indeed, a recent communication showed that the very low number of endogenous c-Kit pos CPC-generated cardiomyocytes detected in the Kitcre mice simply reflects the failure to recombine the CPCs to track their progeny and the severe defect in CPC myogenesis produced by the Kitcre allele [70] .
Over the years, accumulated evidence from human and mouse studies demonstrate that cardiac aging and pathology affects the activity and potency CPCs [71] [72] [73] [74] . This translates into a diminished capacity of the aged and diseased myocardium to maintain homeostasis, and repair and regenerate following injury [75] [76] [77] [78] [79] [80] . The aging milieu might therefore limit the success of cell transplantation therapies where the outcome is direct cardiogenic differentiation of transplanted cells and/or stimulation of endogenous regenerative mechanisms. As the majority of cardiovascular disease patients in need of regenerative therapies are of advanced age, regulation of CPC and cardiovascular aging/senescence is mission critical.
Here we provide new information about the existence and biology of CPCs and further show their importance and relevance in the aged and diseased human heart, which we hope will help resolve the controversy plaguing this important field. Indeed, we have carried out an extensive analysis of CPCs in the human failing heart with advanced age and show the accumulation of senescent-CPCs, which exhibit diminished self-renewal, differentiation, and regenerative potential in vivo. We show that Senescent-CPCs have a SASP that negatively affects healthy non-senescent, cycling-competent CPCs, rendering them senescent. Clearing the senescent-CPCs using combinations of senolytic drugs attenuates the SASP and its effect on promoting senescence in vitro. The effects of global elimination of senescent cells on the heart and its regenerative capacity have not been elucidated. We report novel data that show systemic elimination of senescent cells in vivo in aged mice using senolytics (D+Q) or using the 'suicide' transgene, INK-ATTAC with administration of AP20187, results in CPC activation and increased number of small, immature, proliferating cardiomyocytes in the aged mouse heart.
Results

CPCs exhibit a senescent phenotype with increased age
Human CPCs were isolated from biopsies of right atria, obtained from subjects who had given informed consent before undergoing cardiac surgery (aortic disease, valve disease, coronary artery bypass graft (CABG), or multiple diseases), using sequential enzymatic digestion and dissociation, Optiprep density gradient to remove large debris, followed by magnetic activated cell sorting (MACS) (Supplementary Figure 1a ). CPCs were magnetically enriched based upon a CD45-negative, CD31-negative, CD34-negative, and ckit-positive sorting strategy [81] (Supplementary Figure 1b) . Despite being recognised as a CPC marker, cells were not sorted for Sca-1 because its homology has not been confirmed in any species other than mouse. By flow cytometry analysis, CPCs showed expression of other recognised CPC markers such as CD90 (37±0.4%), CD166 (41±1%), CD105 (13±1%), and CD140α (5±0.4%) (Supplementary Figure 1c) .
We isolated CPCs from 35 subjects of different genders, ages, and pathologies and found a linear increase (R 2 =0.722) in the number of CPCs that expressed the senescence-associated marker, p16 INK4A , with age (Figure 1a ). No differences were evident between males and females for p16 INK4A expression or between aortic disease, valvular disease, coronary artery disease, and multiple other diseases for p16 INK4A expression ( Supplementary Figure 2a, 
b).
On average, 22±9%, 31±4%, 48±9%, and 56±16% of CPCs expressed p16 Ink4a isolated from 50-59, 60-69, 70-79, and 80-89 year old subjects, respectively. We also found an increase (P<0.05) in the number of senescence-associated β-galactosidase-(SA-β-gal; ~60%) and DNA damage marker, γH2AX-positive CPCs (~20%) isolated from old (71-79 years), compared to middle-aged (54-63 years) subjects (Figure 1b,c) . Moreover, p16 INK4A -positive CPCs co-expressed γH2AX (Figure 1c) . Further interrogation by Q-FISH revealed that, while the average telomere length of CPCs isolated from old and middle-aged subjects' hearts were comparable, CPCs isolated from old (78-84 years) subjects' hearts contained a 12% subpopulation with telomere length of <6Kb, which is regarded as being critically short (Figure 1d ) [82] . Approximately 2% of the CPCs isolated from human hearts were Ki67positive, reflective of their mainly dormant, quiescent phenotype [83] . There were no differences between middle-aged and old subjects in number of Ki67-positive CPCs, and we did not see any Ki67-positive CPCs that were p16 INK4A -positive (Supplementary Figure 2c) .
These findings indicate that the aged human heart contains an increased proportion of aged senescent-CPCs, which could translate to their dysfunctionality.
CPCs from old subjects show impaired cell growth and differentiation
CPCs were isolated from 5 old (76-86 years) and 8 middle-aged (32-66 years) subjects, plated in growth medium, and propagated, where possible, to passage 11. CPCs isolated from 2 of the middle-aged (32 and 61 years) and 3 of the oldest (78, 80, and 86 years) subjects failed to grow and become established in vitro. Of the CPC cultures that did grow from all age groups (n=8), the CPCs, from P3 to P11, gradually lost their p16 INK4A Older subject's differentiated CPC-derived precursor cells showed disorganised sarcomeric structure (Figure 2e ) and decreased (P<0.05) expression (Figure 2g ), compared to differentiated CPCs from younger, middle-aged subjects.
Even though CPCs isolated from old hearts showed decreased proliferation, clonogenicity, and differentiation potential, only ~50% of CPCs are senescent in old myocardium (Figure  1a ), therefore these data imply that a functionally cycling-competent CPC population still exists in old myocardium. Indeed, single CPC-derived clones from young, middle-aged, and old subjects were indistinguishable in terms of morphology, senescence, multipotency, selfrenewing transcript profile, and differentiation (Supplementary Figure 3) . These findings suggest that CPCs age and become senescent in a stochastic, non-autonomous manner. This resembles what was seen in rat preadipocytes [84] .
Aged-senescent CPCs lose their regenerative capacity in vivo
To purify for a senescent population of CPCs we utilised the C 12 -5- To determine whether the dysfunctional stem/progenitor cell properties of the senescent-CPCs translated in vivo, we tested the regenerative capacity of senescent SA-β-gal-positive CPCs and cycling-competent SA-β-gal-negative CPCs in the myocardial infarctionregeneration mouse model (Figure 3a) . Male, immunodeficient NSG mice were subjected to permanent ligation of the left anterior descending (LAD) coronary artery. Immediately after ligation, 5 x 10 5 SA-β-gal-positive senescent or SA-β-gal-negative cycling-competent CPCs were injected intramyocardial in 15µl of PBS at 2 sites in the border zone. To serve as a cell control, a separate set of MI-mice were injected with 5 x 10 5 non-CPCs (c-kit neg cardiacderived cells; containing 86±5% cardiac fibroblasts, 13±3% vascular smooth muscle, 1±1% endothelial cells [40] ). Sham animals were treated the same way, except ligation of LAD coronary artery was not performed and they did not receive cells but were injected with the same volume of PBS. Mice were administered BrdU via osmotic mini pumps for 14 days after MI and cell injection to track new cell formation (Figure 3a) . All cell populations were labelled prior to injection with PKH26 lipophilic membrane dye, which exhibited high labelling efficiency and label dye retention over population doublings in cycling-competent CPCs and c-kit neg cardiac-derived cells in vitro (Supplementary Figure 7) . We sacrificed a sub-set of MI-mice that had been injected with 5 x 10 5 SA-β-gal-negative cycling-competent 
Aged-Senescent CPCs have a Senescence-Associated Secretory Phenotype (SASP)
Senescent cells exhibit a SASP [10] . Senescent SA-β-gal-positive CPCs showed increased (Figure 4d-f) . These findings show that the senescent-CPCs exhibit a SASP, which can negatively impact surrounding cells, rendering otherwise healthy, cyclingcompetent CPCs to lose proliferative capacity and switch to a senescent phenotype.
Elimination of senescent CPCs using senolytic drugs abrogates the SASP in vitro
Removal of p16 Ink4a senescent cells can delay the acquisition of age-related pathologies in adipose tissue, skeletal muscle, heart, blood vessels, lung, liver, bone, and eye [9, 11, 12, 16-20, 24, 25, 28] . Recent studies have documented the use of senolytic drugs for the selective clearance of senescent cells from 'aged' tissues [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . We tested the potential of 4 senolytic drugs, Dasatinib (D; an FDA-approved tyrosine kinase inhibitor), Quercetin (Q; a flavonoid present in many fruits and vegetables), Fisetin (F; also a flavonoid), and Navitoclax (N; an inhibitor of several BCL-2 family proteins), alone and in combination to eliminate and clear senescent-CPCs in vitro (Supplementary Figure 9a) . Measuring cell viability with crystal violet and number of SA-β-gal-positive CPCs, dose-response experiments on senescent-or cycling-competent CPCs from the same subjects showed D and N to effectively clear senescent-CPCs, whereas F and Q were less effective at clearing senescent-CPCs (Supplementary Figure 9b,c) . However, D also decreased the viability of cycling-competent CPCs (Supplementary Figure 9b) . A combination of D+Q, which has previously shown to yield effective senescent cell clearance [16-20, 24, 25] and which does not share the toxic anti-neutrophil and anti-platelet side effects of N [22, 23] was tested, and at a dose of 0.5µM D with 20µM Q, cycling-competent CPC viability was preserved (Figure 5a ), but senescent-CPCs were cleared and induced to selective apoptosis (Supplementary Figure 9d) . (Figure 5j,k) . Co-culture of cycling-competent CPCs with senescent-CPCs led to increased (P<0.05) secretion of SASP factors into the medium, but the level of SASP factors was reduced (P<0.05) with application of D+Q (Figure 5l) . These findings document that senescent CPCs have a SASP, and clearance of senescent CPCs using a combination of D+Q senolytics abrogates the SASP and its detrimental senescenceinducing effect on healthy, cycling-competent CPCs.
Elimination of senescent cells in vivo activates resident CPCs and increases number of small, proliferating cardiomyocytes in the aged heart
Eliminating a relatively small proportion (~30%) of senescent cells using a 'suicide' transgene, INK-ATTAC, that permits inducible elimination of p16 Ink4a -expressing senescent cells upon the administration of a drug (AP20187) extends health span and prevents the development of multiple age-related morbidities in both progeroid and normal, chronologically aged mice [9, [16] [17] [18] [19] [20] 28] . Moreover, in 20-month-old male C57BL/6 mice either randomized to vehicle or D+Q treatment once monthly for 4 months, D+Q treatment led to significantly lower senescent (p16 Ink4a -and SA-β-gal-expressing) cells in bone, adipose tissue, skeletal muscle, and kidney [16] [17] [18] [19] [20] 24] . Here 24-32 month INK-ATTAC transgenic or wild-type mice were randomised to either vehicle, AP20187, or D+Q treatment, administered in 4 cycles for 3 consecutive days/cycle, 12 days apart. Mice were sacrificed 4 days after the last dose of cycle 4 (Figure 6a ). Tissues in which p16 Ink4a expression and/or senescent cells are decreased by D+Q in wild type mice as well as by AP20187 in INK-ATTAC mice include the aorta, adipose tissue, cardiac and skeletal muscle, lung, liver, and bone [9, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] .We showed p16 Ink4a mRNA expression was decreased (P<0.05) in the heart following D+Q or AP20187 treatment in aged INK-ATTAC or wildtype mice (Figure 6b ).
Previously we have shown an improvement of heart function in old mice after D+Q treatment [24] . Analysis of cardiac cross-sections revealed significantly higher (P<0.05) CPC (Sca- (Figure 6c; Supplementary Figure 10a Figure 10b) . Morphometric analysis of heart sections showed that AP20187-treated and D+Q-treated mice had increased number of smaller ventricular myocytes (Figure 6d ), suggesting these myocytes to be immature and newly formed, compared to vehicle-treated mice, which exhibited only rare small myocytes but a greater proportion of hypertrophied myocytes (Figure 6d) . We found an increase (P<0.05) of small, proliferating Ki67-positive myocytes (~0.25%) in old hearts following AP20187-or D+Qtreatment, compared to vehicle-treated control (0.03±0.03%) (Figure 6e,f) . To corroborate these data we injected EdU 4 days and 2 hours prior to sacrifice of old (22m) and young (3m) AP20187-treated INK-ATTAC mice (Supplementary Figure 10c) . We found increased (Figure 6h) , CPC numbers or myocyte diameter (data not shown). These findings show that clearance of senescent cells leads to stimulation of CPCs and cardiomyocyte proliferation and that this strategy is specific to the aged heart.
Discussion
In a large sample cohort our study shows that CPCs isolated from the failing human heart develop a senescent phenotype with age exhibited by increased expression of senescenceassociated markers (p16 INK4A , SA-β-gal), DNA damage, shortened telomere length and a SASP. Aged human hearts with dilated cardiomyopathy showed greater numbers of p16 INK4A -positive CPCs and cardiomyocytes with shorter telomeres than age-matched controls [72] .
Similarly, CPCs isolated from failing, aged hearts show increased p16 INK4A and inflammatory factor expression [73] . Reliably detecting senescent cells in vivo is an ongoing challenge, and it is important that a combination of senescent cell biomarkers are used for detection as any Moreover, strategies to activate the regenerative capacity of the aged heart through delivery of growth factors or cell therapy will also be sub-optimal. Therefore, the success of cardiac regenerative therapeutic approaches thus far tested for treating patients with heart failure and disease could be of limited efficacy in promoting myocardial regeneration because of the increased number of senescent, dysfunctional CPCs and cardiomyocytes [72, 73] and the resultant presence of a cardiac SASP in the aged and failing heart that impairs the function of the remaining non-senescent CPCs.
The present study found that CPCs age in a stochastic non-autonomous manner and it is possible to clonally select for a cycling-competent population of CPCs even from diseased or aged hearts. There are individual CPCs in older individuals that have replicative and functional capacities resembling those of CPCs in younger subjects. A similar scenario was found in the case of rat fat cell progenitors [84] . While the abundance of progenitors cloned from adipose tissue that had restricted capacities for replication and differentiation into adipocytes or that were non-replicative but viable (i.e., senescent) increased progressively with aging in rat fat, there remained cells that had the capacities for replication and adipogenic differentiation characteristic of clones derived from young rats. Together, these findings indicate that: (1) it may be feasible to isolate CPCs even from older individuals that are functional, capable of supporting cardiac regeneration if removed from their toxic milieu, and that could be therapeutically relevant in treating patients, especially if they were autologously generated [85] and (2) that by clearing senescent CPCs with a toxic SASP from the aged heart, there remains a tissue-resident population of CPCs with capacity to regenerate damaged heart tissue.
When we purified for a homogenous SA-β-gal-positive, senescent CPC population, we showed that these cells had poor engraftment and survival, and were unable to contribute to cardiac regeneration, repair or restoration of cardiac function following transplantation into the infarcted myocardium. This is contrary to in vitro-selected, SA-β-gal-negative, proliferative cycling-competent (Ki67 pos ) CPCs, which had high survival and engraftment in the infarct/border zone, restored cardiac function almost to baseline and sham control values (LVEF 59±2% at 28 days vs. 66±2 at baseline), decreased infarct size, differentiated into endothelial and cardiomyocyte-like precursor cells as well as enhanced endogenous new cardiomyocyte and capillary formation. Injection of CPCs that show high survival and engraftment [60] , and have the ability to generate new cardiomyocytes and vasculature [40, 48, 81, 83] can facilitate physiologically significant repair and regeneration, with resultant improvements in cardiac function in both humans [66] and rodent models [40, 43, 45, 48, 61, 83, 86] . Although some of the transplanted CPCs expressed α-sarcomeric actin, these cells did not exhibit the typical cardiomyocyte phenotype as they were small and lacked a structured sarcomeric unit. Therefore, they could not be considered as new, immature myocytes which contributed physiologically to the substantially improved LV function.
There is now a general consensus that the favourable effect of cell transplantation protocols is, at least in part, mediated by 'paracrine' effectors secreted by the transplanted cells, contributing to improved myocardial contractility and amelioration of ventricular remodelling (decreasing fibrosis, hibernation, and stunning), inhibition of the inflammatory response, increased cardiomyocyte survival, cardiomyogenesis and angiogenesis/neovascularisation [87] . The present data emphasize the importance of taking into account the hostile infarcted environment, which does not favour engraftment, differentiation or maturation of newly formed cardiomyocytes derived from injected cells. However, the presence of CPC-derived cardiomyocyte precursors expressing sarcomeric protein in the infarct/border zone is promising and further work should elucidate how to mature these cells into functionally competent contractile cells.
Like the present study, not all experimental studies have shown physiological regeneration of CPC-derived cardiac muscle following administration of CPCs [60, 88] . This is most likely due to the heterogeneous nature of cardiac c-kit positive cells tested, with only a very small fraction (1-2%) being cardiomyogenic [83] . Bringing together the cardiomyogenic potential of CPCs, which can be amplified in number through in vitro clonal selection [40, 83] and CPC-mediated cytokine release that regulates cardiac cells' behavior, advocate CPCs as an ideal cell candidate for cardiac regenerative therapies.
Senescent cells have emerged as bona fide drivers of aging and age-related CVD, which suggests strategies aimed at reducing or eliminating senescent cells could be a viable target to treat and prevent CVD [89] . Baker et al. (2016) showed in 18 month old INK-ATTAC mice that p16 INK4a -positive cells contribute to cardiac aging and these senescent cells decreased following AP20187-treatment [28] . We show for the first time that the genetic and pharmacological approaches used here to reduce senescent cell burden leads to activation of the endogenous regenerative capacity in the aged heart. AP20187-treated INK-ATTAC and D+Q-treated INK-ATTAC and wild-type aged mice had an increased number of CPCs and smaller ventricular myocytes, which were Ki67-positive and EdU-positive, suggesting these myocytes to be immature and newly formed, compared to vehicle-treated mice, which exhibited very rare small myocytes but a greater proportion of hypertrophied myocytes. Although clearing senescent cells using a genetic approach is not feasible in humans, the senolytic (D+Q) pharmacological approach described here is clearly translatable and can be used to target a fundamental aging mechanism present in most tissues, including the heart.
Pharmacologically eliminating senescent cells or inhibiting the production of their SASP has been shown to improve cardiovascular function [16, 24] , physical function [20] , enhance insulin sensitivity [11] , prevent age-related bone loss [17] , reduce frailty, and increase lifespan and health span [13, 20] . Indeed, D+Q administration over 3 months decreased senescent cell markers (TAF+ cells) in the media layer of the aorta from aged (24 months) and hypercholesterolemic mice, which was met with improved vasomotor function [16] . The approaches used in the present study, and thus far in previous studies, target global elimination of all senescent cells. Therefore, whether cell-specific elimination or local delivery of senolytics results in a greater effect in eliminating senescent cells and rejuvenating tissue regenerative capacity is yet to be determined.
Previous work has shown that senescent human primary preadipocytes as well as human umbilical vein endothelial cells (HUVECs) develop a SASP with aging, and conditioned medium from senescent human preadipocytes induced inflammation in healthy adipose tissue and preadipocytes [13] . Recently, the translational potential of using D+Q senolytics on Clearance of senescent human CPCs using D+Q in the present study also abrogated the SASP, and the deleterious impact of the SASP on impairing proliferation and inducing senescence to healthy, cycling competent CPCs in a co-culture environment was abolished with D+Q treatment. Thus D+Q can kill human senescent cells, including tissue specific stem/progenitor cells, and can attenuate the secretion of inflammatory cytokines associated with human age-related frailty [20] .
The anthracycline doxorubicin (DOX) is an effective chemotherapeutic agent used to treat pediatric cancers, but is associated with progressive and dose-related cardiotoxicity that may not manifest itself until many years after treatment. In a juvenile mouse model of anthracycline-mediated late onset cardiotoxicity, Huang et al. [91] reported decreased number of CPCs, which showed impaired differentiation into the cardiomyocyte and endothelial lineage in the MI-border zone of animals that had been exposed to DOX as pups. DOX treatment also led to significantly less CPCs in the juvenile heart, and those that remained showed decreased proliferation and increased expression of p16 Ink4a at 12 days of age.
Moreover, 72 hours of DOX treatment (10nM or 100nM) on isolated CPCs in vitro led to attenuated proliferation, reduced telomerase activity and induced expression of p16 Ink4a [91] .
The present study showed that DOX treatment (0.2µM) for 24 hours to CPCs induced p16 Ink4a , γH2AX and SA β-gal expression evidencing that CPCs had become senescent following DOX exposure. Future work should focus on the regenerative capacity of the heart following DOX exposure and whether senolytics could be used following DOX treatment and in later life to eliminate senescent cells and rejuvenate CPCs and the regenerative potential of the heart.
In conclusion, the present work demonstrates that in the aged and failing human heart a large majority of its resident CPCs are senescent and dysfunctional exhibiting impaired proliferation, clonogenicity and differentiation potential. Importantly, senescent CPCs have a SASP that can negatively affect cell behavior and render neighbouring cells into senescence.
Elimination of senescent human CPCs in vitro attenuates the SASP and its deleterious effect.
Senescent human CPCs are unable to contribute to repair and regeneration of the MI heart, in contrast to cycling competent, healthy human CPCs, which facilitate reparative processes in the damaged myocardium restoring LV function. The present work demonstrates approaches that eliminate senescent cells may be useful for treating age-related cardiac deterioration and rejuvenating the regenerative capacity of the aged heart. The next steps would be to determine whether senolytic approaches could be used in conjunction with cell therapy interventions to improve the environment (the 'soil') the cells (the 'seeds') are being transplanted into and the intrinsic reparative mechanistic processes that are compromised with age. Indeed, targeting senescent cells could also impact the potency of resident stem/progenitor populations in other aged organs. The present findings provide new insights into therapies that target senescent cells to prevent an age-related loss of regenerative capacity.
Methods
Human CPC isolation
Myocardial samples (~200mg each) were obtained from the right atrial appendage (n=119) of subjects with cardiovascular disease, aged 32-86 years. All subjects had given informed consented to take part in the study (NREC #08/ H1306/91). Samples were stored in saline on ice until ready to process (~1hr). All steps were performed at 4°C unless stated otherwise.
Briefly, cardiac tissue was minced then digested with collagenase II (0.3mg/ml; Worthington Supplementary   Table 1 .
Flow cytometry and FACS
The c-kit pos , CD45 neg , CD31 neg human CPCs were analysed for hematopoietic, mesenchymal, and endothelial cell markers using a FACSCanto II™ flow cytometer (BD) as previously described [92] . The antibodies used for flow cytometry and FACS are reported in Supplementary Table 1 . Respective isotype controls (Biolegend) were used as negative controls for all flow cytometry procedures. All antibodies were applied at 1:10 diluted in incubation media for 30 min at 4°C with agitation. Data were analysed using FlowJo® software (FlowJo LLC).
SA-β-gal pos CPC sorting was performed by fluorescent activated cell sorting (FACS) using
an ImaGene Green C 12 FDG lacZ gene expression kit (Life Technologies, USA) according to the manufacturer's instructions and protocols previously reported [93] . Briefly, freshly isolated CPCs were resuspended in 1ml of 33µM C 12 FDG β-gal diluted in pre-warmed DMEM/F12 media and incubated at 37°C for 30 minutes with agitation. The cell suspension was then sorted based upon SA-β-gal pos fluorescence using FACS.
Cell culture
Human CPCs were cultured on CELLstart™ (ThermoFisher Scientific)-coated cultureware in growth medium, which is composed of (1:1) Dulbecco's MEM/Ham's F12 (DMEM/F12;
Sigma-Aldrich) and Neurobasal A medium (ThermoFisher Scientific) containing 10%
Stemulate® pooled human platelet lysate (Cook medical, USA), 2mM L-alanyl-L-glutamine (ThermoFisher Scientific), B27 and N2 supplements (ThermoFisher Scientific), leukemia inhibitory factor (LIF) (10ng/ml; Millipore), bFGF (10ng/ml; Peprotech), EGF (20ng/ml; Peprotech), insulin-transferrin-selenite (ITS; ThermoFisher Scientific), 1% penicillin/streptomycin (ThermoFisher Scientific), 0.1% gentamicin (ThermoFisher Scientific), and 0.1% Fungizone™ (ThermoFisher Scientific) in a humidified hypoxic incubator at 37°C, 5% CO 2 , 2% O 2 .
Immunocytochemistry
Human CPCs were either freshly isolated or grown in culture and then directly cytospun onto poly-lysine-coated slides using a Shandon Cytospin 4 Cytocentrifuge (ThermoFisher Scientific). Slides were immediately fixed using Shandon Cell-Fixx (ThermoFisher Scientific). After fixation, cells were allowed to air dry before proceeding with immunostaining. To prepare cells for immunostaining, slides were incubated with 95% ethanol for 15 min at room temperature, washed with PBS, and in the case of intracellular staining, incubated in 0.1% Triton X-100:PBS at room temperature for 10 minutes. After washing with 0.1% tween:PBS and a 1 hr incubation in 10% donkey serum, cells were incubated overnight at 4°C with primary antibodies to p16 InkK4a , γH2AX, or Ki67
( Supplementary Table 2 SA-β-gal (SABG) staining was performed using a SA-β-gal staining kit (Cell Signaling Technology) according to the manufacturer's instructions and protocols previously reported [93] . In brief, human CPCs were either freshly isolated and directly cytospun onto polylysine-coated slides (ThermoFisher Scientific) or grown in culture and then fixed in situ using 2% paraformaldehyde: PBS (vol/vol) (Sigma-Aldrich) for 5 minutes at room temperature.
Following fixation, cells were washed with PBS before being incubated in SABG activity solution (pH 6.0) at 37°C overnight. The enzymatic reaction was stopped by washing slides with ice-cold PBS and SABG staining was fixed with ice-cold methanol for 30s before mounting/visualising. Senescent CPCs were identified as blue-stained cells using light microscopy. A minimum of 10 images were taken at x4 magnification from random fields and the percentage of SA-β-gal cells were expressed as percentage of total nuclei.
Q-FISH analysis
Freshly isolated human CPCs were cytospun and fixed as described above. To perform Q-FISH, slides were prepared using a telomere PNA FISH kit (Dako) according to the manufacturer's instructions. In brief, slides were incubated in 95% ethanol for 5 min and 
Proliferation, clonogenicity, cardiosphere formation and cardiomyocyte differentiation assays in vitro
A BrdU incorporation assay (Roche) was used to determine cell proliferation, as previously described [95] . In brief, 2.5 x 10 3 CPCs were plated in 24 well plates and serum-starved for 6 h in DMEM/F12 medium. Medium was then replaced with growth medium and BrdU was added, 1μg/ml every 8 hours. Cells were fixed after 24 hours and BrdU incorporation was assessed using a BrdU detection kit (Roche) according to the manufacturer's instructions (Supplementary Table 2 ). Nuclei were counterstained with the DAPI (Sigma-Aldrich). Cells were viewed and imaged using an ApoTome fluorescent microscope (Zeiss). A minimum of 10 random fields of view at x20 magnification were analysed and number of BrdU-positive cells expressed as a percent of total nuclei.
Human CPCs (P2-P3) were serially diluted and deposited into CTS CELLstart pre-coated 96well plates (Corning Inc., USA) at 1 cell per well, as described previously [83] . Individual cells were cultured in growth medium which was refreshed every 3 days. Wells containing CPC colonies were scored by bright-field microscopy after 7 days of culture to determine clonal efficiency. The clonogenicity of the human CPCs was expressed as the percent number of clones generated from the total number of single cells plated. A minimum of 3 plates were quantified per subject.
Cardiomyocyte differentiation was induced as previously described [81, 83] . Table 2 ). Secondary antibodies were Alexa Fluor 488, or 594 (Life Technologies). Nuclei were counterstained with DAPI. A minimum of 5 images at x20 magnification from random fields were taken per subject for quantification of Nkx2.5 pos cells per total nuclei and fluorescent intensity of α-sarcomeric actin expression.
Senescence induction, conditioned media, and multiplex SASP protein analysis
To induce senescence pharmacologically, cycling-competent CPCs were exposed to Multiplexing analysis was performed using the Luminex 100 system (Luminex) by Eve Technologies using human multiplex kits (Millipore).
PKH26 cell labelling
Human cycling-CPCs, Senescent-CPCs or c-kit neg cells (5x10 5 ) were harvested and washed in serum-free DMEM/F12 medium before being resuspended in 25µl diluent C (Sigma-Aldrich). An equal volume of PKH26 labelling solution (4µM; Sigma-Aldrich) was added to the cell suspension and mixed thoroughly. Cells were incubated for 2 minutes at room temperature in the dark, before adding an equal volume of DMEM/F12 + 10% FCS to halt the labelling reaction. Cells were then centrifuged and washed three times in PBS before transferring to a new Eppendorf tube and re-suspending in 15µl PBS for transplantation in vivo. Initial PKH26 labelling was validated using flow cytometry compared to unlabelled cells. PKH26 labelled cycling CPCs and c-kit neg cells were also propagated in vitro to monitor label retention over culture passage (P1-P9). To quantify PKH26 pos labelling, cells were cytospun and counterstained with DAPI. The total number of positive cells per total nuclei were quantified from a minimum of 5 random fields at x20 magnification.
Acute myocardial infarction model
The Echocardiography measurements were taken at baseline (BL), 7 days, and 28 days post-MI, after which mice were sacrificed.
Senolytic drug treatment, viability, TUNEL staining in vitro
Cycling-competent human CPCs and Senescent-CPCs, induced by Doxorubicin (as described 
Co-culture assays
CPCs were plated in the bottom well of 0.4µm pore Costar Transwell 24-well plates (Corning) and, once attached, were induced to senescence with Doxorubicin as described above and maintained for 30 days. Cycling-competent CPCs were plated at low density (200 cells/well) onto the Transwell membrane 1 day prior to co-culture. Cycling-competent CPCs were then combined with either senescent CPCs or cultured alone (control wells) and maintained for 7 days. At this time point, cultures were either fixed for analysis, conditioned media were collected, or senolytics were applied to transwells for 3 days to selectively clear senescent cells (as described above). After senolytic clearance, a sub-set of wells were fixed and stained for SA-β-gal (as described previously) to confirm effective clearance. Cyclingcompetent CPCs were maintained for a further 7 days, at which point conditioned media were collected for luminex analysis (as described above) and cultures fixed for analysis.
INK-ATTAC mice and drug treatments
The following experimental procedures were conducted in accordance with Mayo Clinic Institutional Animal Care and Use Committee (IACUC) guidelines. Both stocks of INK-ATTAC and C57BL/6 wild type mice were bred and aged at Mayo Clinic. The generation and characterization of INK-ATTAC mice has been described previously [9, 11] [11, 16] . Another group of INK-ATTAC mice aged 3 months (n=10) and 22 months (n=10) were randomly assigned to treatment groups and injected intraperitoneally (i.p.) with either vehicle or AP20187 for 2 consecutive days every 2 weeks for 2 months as shown in Supplementary Fig 10c. These mice were injected (i.p) with EdU (123 mgkg -1 ) 2 hours prior to sacrifice.
Tissue collection, immunohistochemistry, and confocal imaging
Mice were sacrificed at either 4 days or 28 
Real-time quantitative polymerase chain reaction (RT-qPCR)
To measure human gene expression, total cellular RNA was extracted and reverse transcription was performed as described previously [92] . RT-qPCR reactions were run with SYBR Green PCR Master Mix (Bio-Rad) and primers (IDT) ( Supplementary Table 3 ).
Human GAPDH, B-actin, and TBP were used as reference genes. qPCR conditions were as follows: 95°C for 5 min, 40 × (95°C for 15s, 60°C for 30s, and 72°C for 30s). All reactions were run in triplicate on a CFX-connect Real-Time PCR System (Bio-Rad) and analyzed using Graphpad software.
From mouse hearts, total RNA was extracted using Trizol (Thermo Fisher Scientific) and reverse transcription was performed using an M-MLV reverse transcriptase kit as described previously [13] . To measure total p16 Ink4a expression, RT-qPCR reactions were performed with TaqMan (Applied Biosystems, Carlsbad, CA) Fast Advanced Master Mix and TaqMan primer-probe gene assay (Thermo Fisher Scientific). Mouse TATA-binding protein (TBP) was used as a reference gene and all reactions were run in triplicate on an ABI Prism 7500 fast Real Time System (Applied Biosystems, Carlsbad, CA) and analyzed using Graphpad software.
Statistical analysis
Data are reported as mean ± SEM or mean ± SD. The data displayed normal variance. The experiments were not randomized, except for the in vivo animal studies as described above.
The investigators were blinded to allocation during experiments and outcome assessment.
Significance between 2 groups was determined by Student's t-test and in multiple
comparisons by the analysis of variance (ANOVA) using GraphPad Prism (GraphPad Software). In the event that ANOVA justified post-hoc comparisons between group means, these were conducted using Tukey's multiple-comparisons test. P<0.05 was considered significant. 
